Goldman Sachs’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-24,200
| Closed | -$51K | – | 4439 |
|
|
2018
Q3 | $51K | Buy |
24,200
+11,801
| +95% | +$24.9K | ﹤0.01% | 4022 |
|
|
2018
Q2 | $29K | Sell |
12,399
-49,812
| -80% | -$117K | ﹤0.01% | 4106 |
|
|
2018
Q1 | $198K | Buy |
62,211
+10,105
| +19% | +$32.2K | ﹤0.01% | 3861 |
|
|
2017
Q4 | $214K | Buy |
52,106
+24,653
| +90% | +$101K | ﹤0.01% | 3805 |
|
|
2017
Q3 | $124K | Sell |
27,453
-142,986
| -84% | -$646K | ﹤0.01% | 3997 |
|
|
2017
Q2 | $568K | Sell |
170,439
-155,991
| -48% | -$520K | ﹤0.01% | 3469 |
|
|
2017
Q1 | $3.01M | Buy |
326,430
+283,558
| +661% | +$2.61M | ﹤0.01% | 2489 |
|
|
2016
Q4 | $331K | Buy |
42,872
+11,386
| +36% | +$87.9K | ﹤0.01% | 3665 |
|
|
2016
Q3 | $360K | Buy |
31,486
+4,394
| +16% | +$50.2K | ﹤0.01% | 3621 |
|
|
2016
Q2 | $334K | Sell |
27,092
-29,519
| -52% | -$364K | ﹤0.01% | 3573 |
|
|
2016
Q1 | $572K | Buy |
56,611
+42,274
| +295% | +$427K | ﹤0.01% | 3153 |
|
|
2015
Q4 | $323K | Buy |
14,337
+5,440
| +61% | +$123K | ﹤0.01% | 3476 |
|
|
2015
Q3 | $148K | Buy |
+8,897
| New | +$148K | ﹤0.01% | 4004 |
|
|
2014
Q2 | – | Sell |
-14,076
| Closed | -$474K | – | 4635 |
|
|
2014
Q1 | $474K | Sell |
14,076
-12,978
| -48% | -$437K | ﹤0.01% | 3409 |
|
|
2013
Q4 | $799K | Buy |
27,054
+13,595
| +101% | +$402K | ﹤0.01% | 3187 |
|
|
2013
Q3 | $206K | Buy |
+13,459
| New | +$206K | ﹤0.01% | 3825 |
|